title: Breast cancer susceptibility risk associations and heterogeneity by E-cadherin tumor tissue expression.
abstract: E-cadherin is involved in cell-cell adhesion and epithelial-to-mesenchymal transitions. In cancers, loss or inactivation of E-cadherin is associated with epithelial cell proliferation and invasion. Here, we sought to determine, if risk associations for 18 breast cancer susceptibility single nucleotide polymorphisms (SNPs) differed by E-cadherin tumor tissue expression in the Polish Breast Cancer Study (PBCS), using data on 1,347 invasive breast cancer cases and 2,366 controls. E-cadherin expression (low/high) was assessed using immunohistochemical staining of tumor tissue microarrays. Replication data on 2,006 cases and 6,714 controls from the Study of Epidemiology and Risk Factors in Cancer Heredity was used to follow-up promising findings from PBCS. In PBCS, we found the rs11249433 SNP at the 1p11.2 locus to be more strongly associated with risk of E-cadherin low tumors (OR = 1.30, 95 % CI = 1.08-1.56) than with E-cadherin high tumors [OR = 1.06, 95 % CI = 0.95-1.18; case-only p-heterogeneity (p-het) = 0.05]. Findings in PBCS for rs11249433 were replicated in SEARCH. Combined analyses of the two datasets for SNP rs11249433 revealed significant heterogeneity by E-cadherin expression (combined case-only p-het = 0.004). Further, among carriers of rs11249433, the highest risk was seen for E-cadherin low tumors that were ER-positive and of lobular histology. Our results in two independent data sets suggest that rs11249433, which is located between the NOTCH2 and FCGR1B genes within the 1p11.2 locus, is more strongly associated with risk of breast tumors with low or absent E-cadherin expression, and suggest that evaluation of E-cadherin tumor tissue expression may be useful in clarifying breast cancer risk factor associations.
authors.affiliation: Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Rockville, MD, USA, hisani.horne@nih.gov.
authors.forename: Hisani N
authors.initials: HN
authors.lastname: Horne
authors.forename: Mark E
authors.initials: ME
authors.lastname: Sherman
authors.forename: Montserrat
authors.initials: M
authors.lastname: Garcia-Closas
authors.forename: Paul D
authors.initials: PD
authors.lastname: Pharoah
authors.forename: Fiona M
authors.initials: FM
authors.lastname: Blows
authors.forename: Xiaohong R
authors.initials: XR
authors.lastname: Yang
authors.forename: Stephen M
authors.initials: SM
authors.lastname: Hewitt
authors.forename: Catherine M
authors.initials: CM
authors.lastname: Conway
authors.forename: Jolanta
authors.initials: J
authors.lastname: Lissowska
authors.forename: Louise A
authors.initials: LA
authors.lastname: Brinton
authors.forename: Ludmila
authors.initials: L
authors.lastname: Prokunina-Olsson
authors.forename: Sarah-Jane
authors.initials: SJ
authors.lastname: Dawson
authors.forename: Carlos
authors.initials: C
authors.lastname: Caldas
authors.forename: Douglas F
authors.initials: DF
authors.lastname: Easton
authors.forename: Stephen J
authors.initials: SJ
authors.lastname: Chanock
authors.forename: Jonine D
authors.initials: JD
authors.lastname: Figueroa
mesh_terms: D000328:Adult; D000368:Aged; D000483:Alleles; D014408:Biomarkers, Tumor; D001943:Breast Neoplasms / Q000235:genetics* / Q000378:metabolism; D015820:Cadherins / Q000235:genetics* / Q000378:metabolism; D016022:Case-Control Studies; D005260:Female; D018740:Genetic Heterogeneity; D020022:Genetic Predisposition to Disease; D006801:Humans; D007150:Immunohistochemistry; D008875:Middle Aged; D016017:Odds Ratio; D020641:Polymorphism, Single Nucleotide; D012307:Risk Factors; D055815:Young Adult
chemical_list: D014408:Biomarkers, Tumor; D015820:Cadherins